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Abstract
Clostridium perfringens is a gram-positive anaerobic rod that is classified into 5 toxinotypes (A,
B, C, D, and E) according to the production of 4 major toxins, namely alpha (CPA), beta (CPB),
epsilon (ETX) and iota (ITX). However, this microorganism can produce up to 16 toxins in
various combinations, including lethal toxins such as perfringolysin O (PFO), enterotoxin (CPE),
and beta2 toxin (CPB2). Most diseases caused by this microorganism are mediated by one or more
of these toxins. The role of CPA in intestinal disease of mammals is controversial and poorly
documented, but there is no doubt that this toxin is essential in the production of gas gangrene of
humans and several animal species. CPB produced by C. perfringens types B and C is responsible
for necrotizing enteritis and enterotoxemia mainly in neonatal individuals of several animal
species. ETX produced by C. perfringens type D is responsible for clinical signs and lesions of
enterotoxemia, a predominantly neurological disease of sheep and goats. The role of ITX in
disease of animals is poorly understood, although it is usually assumed that the pathogenesis of
intestinal diseases produced by C. perfringens type E is mediated by this toxin. CPB2, a
necrotizing and lethal toxin that can be produced by all types of C. perfringens, has been blamed
for disease in many animal species, but little information is currently available to sustain or rule
out this claim. CPE is an important virulence factor for C. perfringens type A gastrointestinal
disease in humans and dogs; however, the data implicating CPE in other animal diseases remains
ambiguous. PFO does not seem to play a direct role as the main virulence factor for animal
diseases, but it may have a synergistic role with CPA-mediated gangrene and ETX-mediated
enterotoxemia. The recent improvement of animal models for C. perfringens infection and the use
of toxin gene knock-out mutants have demonstrated the specific pathogenic role of several toxins
of C. perfringens in animal disease. These research tools are helping us to establish the role of
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each C. perfringens toxin in animal disease, to investigate the in vivo mechanism of action of these
toxins, and to develop more effective vaccines against diseases produced by these
microorganisms.
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INTRODUCTION
Clostridium perfringens is a gram-positive anaerobic rod that is classified into 5 toxinotypes
(A, B, C, D, and E) according to the production of 4 major toxins, namely alpha (CPA), beta
(CPB), epsilon (ETX) and iota (ITX) (Table 1). However, this microorganism can produce
up to 16 toxins in various combinations, including lethal toxins such as perfringolysin O
(PFO), enterotoxin (CPE), and beta2 toxin (CPB2) [1–4].
C. perfringens causes numerous gastrointestinal infections in most mammalian species
(Table 2). These infections are generically called enterotoxemias because toxins produced in
the intestine may be absorbed into the general circulation. However, while this is true for
many C. perfringens toxins, some toxins produced in the intestine act only locally. This
microorganism can also cause diseases of skin, subcutaneous and muscular tissues (gas
gangrene or malignant edema). Most, if not all diseases produced by C. perfringens are
mediated by one or more of its powerful toxins. We review here the most studied C.
perfringens toxins involved in mammalian veterinary diseases.
ALPHA TOXIN (CPA OR PLC)
Structure and Mechanism of Action
Alpha-toxin (CPA or PLC) is produced by all C. perfringens strains (Table 1), although
toxinotype A strains usually produce higher amounts than the other toxinotypes [5]. The
main properties of this toxin are summarized in Table 3. CPA is a 43 kDa protein comprised
of 370 amino acids. It contains two domains, an alpha-helical N-terminal domain harboring
the phospholipase C active site, and an alpha-sandwich C-terminal domain which is
involved in membrane binding. CPA has more than 50% identity at the amino acid level,
and/or on the basis of antigenic cross-reactivity, to the phospholipases C from Clostridium
bifermentans, Clostridium novyi, Clostridium baratii and Clostridium absonum [3]. CPA is
a classic example of a toxin that modifies cell membranes by enzymatic activity. This toxin
is a zinc-dependent phospholipase C which degrades phosphatidylcholine and
sphingomyelin, both components of the eukaryiotic cell membranes [6], causing damage on
the membrane of erythrocytes and other cells from many animal species. The net result of
this action is cell lysis, by degradation of membrane phospholipids [7]. CPA also activates
several other membrane and internal cell mechanisms that lead to hemolysis [6–8]. In
addition, CPA activates the arachidonic cascade resulting in the formation of thromboxanes,
leukotrienes and prostaglandins, which activate the inflammation cascade and produce
vasoconstriction [6, 9].
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In combination with PFO, CPA allows C. perfringens to escape macrophage phagosomes
and survive in the host tissue [10]. CPA in sublytic amounts impairs the migration of
leukocytes and promotes their aggregation by several different mechanisms including
hyperadhesion with leucostasis at the periphery of lesions [11]. These free intravascular
aggregates are responsible for the blockade of blood flow in small vessels, and subsequently
for the anoxia and necrosis of tissues [12–15] which in turn helps create anaerobic
conditions for the proliferation of C. perfringens.
Genetics of CPA
All C. perfringens strains possess the gene encoding CPA. This gene (cpa) is
chromosomally encoded and located close to the origin of replication, which is one of the
most stable regions within the bacterial chromosome [16]. This chromosomal location of the
cpa gene contrasts with many of the other major toxin genes of C. perfringens, which are
plasmid borne [16–19]. Nucleotide sequencing of the cpa gene from type A strain ACTC
13124, a high CPA producer, revealed a single open reading frame that includes a putative
prokaryotic signal sequence [20]. The cpa genes from other type A and types B-E strains of
C. perfringens have been characterized, showing that they are also located chromosomally
[16].
A two component regulatory system named VirS/VirR positively regulates the in vitro
transcription of cpa via a RNA regulatory molecule called VR-RNA [21–24]. Transcription
of cpa and production of the CPA protein is also regulated by the recently described C.
perfringens Agr quorum sensing system [25, 26]. Whether those systems act in concert to
regulate cpa transcription still needs to be clarified.
Role of CPA in Animal Diseases
Intestinal Infections—The role of CPA in intestinal disease of mammals is controversial
and poorly documented (Table 2). In sheep, C. perfringens type A causes yellow lamb
disease [27], a rare form of acute enterotoxemia in lambs. Information about pathogenesis of
this disease is minimal and often contradictory, but it is generally assumed that most clinical
signs and lesions are due to the effects of CPA [27]. However, no definitive proof of the
action of this toxin in the pathogenesis of yellow lamb disease has been provided. The
disease is characterized clinically by depression, anemia, icterus, and hemoglobinuria.
Necropsy findings include pale and friable liver and spleen and the presence of red urine in
the urinary bladder [27]. Histopathological changes include periacinar necrosis of the liver,
splenic congestion, nephrosis with hemoglobin casts, and pulmonary congestion and edema
[27].
C. perfringens type A has been and is still frequently blamed for enteritis, abomasitis and/or
enterotoxemia in cattle [28–32], horses [33–39], goats [40–43] and pigs [44, 45]. However,
the role of this microorganism in natural diseases of these species remains controversial and
poorly documented [46]. Although it has been suggested that clinical signs and pathological
findings in several of these diseases may be the result of CPA action, no definitive evidence
has become available that proves the role of CPA in the pathogenesis. While large amounts
of CPA are detected in feces of naturally infected cattle [45] (and some of the species
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mentioned above), CPA is also present in the intestinal content of many clinically healthy
animals by which detection of CPA in intestinal content of sick animals does not have
diagnostic relevance for type A disease.
Results of experimental work with C. perfringens type A or purified CPA suggest that this
microorganism, and probably CPA, can produce disease in several mammalian species [30,
31, 43, 47]. However no definitive proof of this causal relationship has been provided and
the role of this microorganism and its major toxin (CPA) in intestinal disease remains
controversial. Intraruminal inoculation of C. perfringens type A into healthy calves induced
anorexia, depression, bloat, diarrhea, and sometimes death [30, 31]. However, enteric
disease could not be reproduced by the inoculation of large amounts of C. perfringens type
A in the small intestine of cattle [46].
Neonatal pigs experimentally inoculated with C. perfringens type A developed enteropathy
and intragastric administration of CPA to piglets caused disease with symptoms similar to
those seen in naturally acquired disease thought to be caused by C. perfringens type A [43].
Ligated ovine ileal and colonic loops incubated with C. perfringens type A CPA retained
more fluid than control loops due to inhibition of water absorption and developed a mild to
moderate multifocal infiltration of neutrophils in the lamina propria and submucosa. These
results suggested that CPA could be responsible for diseases of intestinal origin in sheep
[48].
The intravascular hemolysis and capillary damage, platelet aggregation, hepatic necrosis and
cardiac effects seen in several animal species, with presumptive type A infection, are
consistent with the action of a circulating toxin such as CPA. Studies with toxin gene
mutants have been performed to study the role of CPA in chickens [49]. However, to our
knowledge, very few studies have been performed involving gastrointestinal tract challenge
exposure of mammals with isogenic C. perfringens type A mutants that do or do not produce
CPA. For instance, vegetative cultures of cpe null mutants of type A that still produce CPA,
did not produce damage to the intestinal mucosa in rabbit ileal loops [50]. Cultures of cpb
null mutants of type C isolates still producing CPA, did not produce fluid accumulation in
rabbit ileal loops [51]. Studies with isogenic C. perfringens toxin mutants in large animals
will be necessary to definitely establish the role of CPA in pathogenesis of intestinal disease
in these species.
Gangrene/Malignant Edema—Studies with isogenic mutants strongly suggest that CPA
is the major C. perfringens toxin involved in gas gangrene in humans [52], which is
characterized by extensive local tissue destruction and necrosis progressing to shock and
death [53, 54].
C. perfringens type A is also involved in gas gangrene (malignant edema) of domestic
mammals including sheep, cattle, goats, and horses, acting alone or in combination with
other clostridial species [55]. Although the condition is most frequently described affecting
subcutaneous tissue and muscle, gangrenous mastitis produced by C. perfringens type A has
also been reported in cattle and sheep [56, authors unpublished observation]. Predisposing
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factors for this disease in animals include trauma associated to injections, shearing,
castration, docking and milking. Although CPA has long been considered the main virulence
factor for malignant edema of animals and vaccines containing alpha toxoid seem to protect
against this disease, no final evidence of the role of CPA in the pathogenesis of malignant
edema has been provided. Also, the fact that most cases of malignant edema in food-
producing animals are associated with a mixed clostridial infection (which may or may not
include C. perfringens type A) suggests that, even if CPA is responsible for some cases of
malignant edema, other clostridial toxins can also produce this disease.
Grossly, malignant edema is characterized by severe subcutaneous and muscular edema,
skeletal muscle necrosis and generalized petechiae on serous membranes, the latter being a
manifestation of terminal disseminated intravascular coagulation due to toxemia.
Histologically, in contrast to other bacterial myonecrosis, C. perfringens gas gangrene and
malignant edema are characterized by a marked absence of inflammatory cells in affected
tissues and the accumulation of leukocytes within vessels at the lesion periphery, most likely
due to the inhibitory effect that CPA has over leukocyte migration.
Experimentally, CPA is lethal for mice, dermonecrotic and hemolytic. When injected
intravenously, CPA suppresses the myocardial contractility and induces hypotension,
bradychardia, shock and multiorgan failure. The myotoxic effects could result from a direct
activity of CPA on muscle cell membrane, from alteration of local blood flow, and/or
inflammatory mediators as a consequence of endothelial cells stimulated by CPA [54]. The
role of CPA in gas gangrene was demonstrated by protection of mice against this disease by
immunization with recombinant CPA, and by reduced virulence of CPA knock-out mutants
of C. perfringens when injected into mice [52].
CLOSTRIDIUM PERFRINGENS BETA TOXIN (CPB)
Structure and Mechanism of Action
The main properties of this toxin are summarized in Table 2. The cpb gene encodes a
prototoxin of 336 amino acids that includes a 27-amino acid signal sequence removed
during secretion, resulting in a mature toxin of ~35 kDa [57, 58]. Purified CPB is
thermolabile, with >90% of its lethal activity being inactivated by incubation for 1 h at 50°C
(or 10 min at 100°C). CPB is also highly sensitive to in vitro trypsin [58, 59] and pepsin [60]
treatment. Low pH does not seem to affect its activity [60].
The deduced CPB amino acid sequence shares similarity with several pore-forming toxins,
including 28% similarity to Staphylococcus aureus alpha-toxin and 22, 28 or 18% similarity
with the A, B, C components of gamma-toxin, respectively [57]. While those toxins cause
hemolysis in erythrocytes from several species [61, 62], CPB is non-hemolytic for rabbit or
sheep erythrocytes [63].
It is interesting that while S. aureus alpha-toxin, and many other pore forming toxins [64],
are cytotoxic for a wide variety of cells [including leukocytes, rabbit kidney cells, smooth
muscle cells and fibroblasts [61], CPB-induced cytotoxicity has thus far only been reported
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for HL-60 cells, HUVEC (human umbilical vein endothelial cell) and intestinal I407 cells
[61,65–68].
Genetics of cpb
CPB is encoded by the cpb gene, which is carried on virulence plasmids [58, 69] of different
molecular size (authors unpublished observations). The cpb gene has been cloned and
sequenced from type B and C isolates, which revealed a very similar ORF of ~1000 bp [57,
70]. A possible Shine-Dalgarno region is located 7 bp upstream of the first ATG start codon.
Despite the proven importance of CPB in type C (and probably type B) disease (see
discussion later), relatively little is known about regulation of the cpb gene in vitro or in
vivo. However, recent studies demonstrated that in the presence of human enterocyte-like
Caco-2 cells, CPB production is rapidly upregulated. The VirS/VirR two component
regulatory system (TCRS) was shown to be involved in modulating this early production of
the CPB protein by upregulating cpb transcription [71].
The VirS/VirR system also controls transcription of other C. perfringens toxins (i.e. pfoA,
plc/cpa, cpb2) by either direct binding of the VirR response regulator to VirR boxes located
upstream of the target gene, or indirectly through RNA regulatory molecules [23, 24, 72–
74]. However, VirR boxes are not detectable within ~800 bp upstream of the cpb gene,
raising the possibility that a regulatory RNA molecule might control cpb transcription via
the VirS/VirR system [74].
Quorum sensing mechanisms provide a molecular signal(s) that activates TCRS [75, 76]. C.
perfringens encodes at least two different quorum sensing systems, i.e. the Lux and the Agr
systems [25, 26, 77]. A type C luxS mutant still normally regulated its cpb transcription and
CPB production, both in vitro and in vivo [26]. Recent studies have found that the C.
perfringens agr locus regulates pfoA and cpa/plc transcription and PFO and CPA/PLC
production, in strain 13 [25, 26]. Additional studies are currently underway to determine the
involvement of this novel system in regulating CPB production.
Role of CPB in Animal Diseases
CPB is responsible for diseases in several animal species (Table 2) and it is produced by
types B and C of C. perfringens. Type B isolates cause an often fatal hemorrhagic dysentery
in sheep, and possibly in other species, while type C isolates cause enteritis necroticans (also
called pigbel) in humans and necrotic enteritis and/or enterotoxemias in almost all livestock
species. Both types B and C animal disease are often accompanied by sudden death or acute
neurological signs [2, 4, 78, 79].
Type B disease is a rare occurrence in farm animals and mostly seen in Middle East
countries and the UK. Clinical disease can be characterized by diarrhea, neurological signs
or both. Post-mortem gross and histopathological findings are similar to those of type C
infections (see below), except for those rare cases of focal symmetrical encephalomalacia,
believed to be due to the effect of ETX [79, 80].
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Clinical signs and histopathologic findings in type C infections are very similar in most
livestock animal species. The course of disease can be peracute, acute, or chronic, with signs
of the acute and peracute condition including intense abdominal pain, depression, and
bloody diarrhea. Chronic disease can occur in older animals of some species (e.g. pigs), and
it is characterized by persistent diarrhea without blood and dehydration [43].
At necropsy, the predominant lesions are most frequently observed in small intestine, but
cecum and spiral colon can sometimes be involved; occasionally, lesions may be confined to
large intestine. Lesions are similar in all segments of intestine, and in acute cases consist of
intestinal and mesenteric hyperemia, diffuse or segmental, extensive fibrinonecrotic
enteritis, with emphysema and bloody gut contents. Mesenteric lymph nodes are red, an
excess of hemorrhagic peritoneal and pleural fluid is found, there may be fibrin strands on
intestinal serosa, and adhesions may develop between intestinal loops.
Histologically, the hallmark of acute disease is hemorrhagic necrosis of the intestinal wall
which starts in the mucosa but usually progresses to affect all layers of the intestine. Lesions
are morphologically similar in all segments of intestine. The luminal surface is covered by a
pseudomembrane composed of degenerated and necrotic desquamated epithelial cells, cell
debris, inflammatory cells, fibrin, and a variable number of large, thick bacilli with square
ends with occasional subterminal spore [81]. The superficial epithelium and layers of lamina
propria are necrotic. Fibrin thrombi occluding superficial arteries and veins of the lamina
propria are characteristic of this condition. Diffuse edema with variable amounts of protein
and inflammatory cell exudate can be seen throughout all intestinal layers, including serosa
[81].
There is currently limited information regarding the pathogenic mechanism of type B-
associated diseases, but some evidence indicates that both CPB and ETX (another potent
toxin produce by type B isolates) may contribute to lethality [82]. The mechanism of
pathogenesis of type C disease is under active investigation. We experimentally
demonstrated that CPB is necessary and sufficient to cause type C pathology in a rabbit ileal
loop model [51]. Type C disease has also been linked to endogenous trypsin deficiency or
the presence, in the intestines, of trypsin inhibitors due to diet. CPB is very trypsin sensitive,
so low trypsin levels or the presence of trypsin inhibitors likely contribute to disease by
favoring CPB persistency in the gastrointestinal tract [2, 51, 83, 84]. Type B and C animal
disease is more frequently seen in neonatal animals than at any other age [4, 5, 79]. This age
predilection is associated to the inhibitory effect that the colostrum has over intestinal
trypsin. This inhibitory effect is an innate mechanism of defense, during the first hours of
life, which protect the immunoglobulins present in the colostrum against protease activity of
trypsin.
C. perfringens types B and C disease begins in the host intestine [2, 4, 79] with absorption
of toxin(s) from the intestines into the circulation that then leads to the death of an infected
animal. Different animal models have been developed to help in understanding the
mechanism of those diseases involving CPB intoxication [51, 83, 85, 86]. Early work
demonstrated that C. perfringens type C could cause a pigbel-like disease in guinea pigs fed
a persistent low protein diet, combined with dietary protease inhibitors [83]. In that study it
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was hypothesized that the low protein diet was a predisposing factor in both humans and
guinea pigs, because of low intestinal protease production in malnourished individuals.
Enteric lesions similar to those observed in human pigbel cases or animals with type C
enteritis were also successfully reproduced by injecting a type C culture, along with a
protease inhibitor, into lambs [84].
The role of CPB in type C-induced intestinal disease has recently been experimentally
demonstrated by inoculating into rabbit ileal loops a series of C. perfringens type C toxin
mutants, along with trypsin inhibitor [51]. Experimental type C pathology induced by wild
type isolate CN3685 was characterized by accumulation of abundant hemorrhagic fluid (Fig.
1), complete loss of absorptive cells along the villi, and coagulation necrosis of the lamina
propria. Confirming the role of CPB, two different cpb mutants were unable to cause fluid
accumulation or intestinal damage, while complementing back CPB expression to the
mutant completely restored virulence (Fig. 1) [51].
For many years, efforts to reproduce intestinal type C disease by injecting purified CPB into
animals had been unsuccessful [4]. However, our recent work reproduced type C pathology
by injecting native CPB, along with trypsin inhibitor, into rabbit intestinal loops [51, 87].
The CPB-induced intestinal lesions, produced in this model, were similar to those described
in type C natural disease [4, 51, 79, 87]. This work was also significant because it
established that purified CPB is a very potent toxin in the rabbit small intestine (i.e. one
microgram was sufficient to cause severe intestinal damage within 1 h) [87].
As mentioned earlier, the lethality of type C infection has long been attributed to absortion
of toxin(s) from the intestine to the circulation. Several studies have proven that purified
CPB is highly lethal for mice [58, 59, 63, 85]. A study by Fisher et al. [85] later
demonstrated, using the mouse intravenous injection lethality model, that CPB is the main
lethal factor present in type C late-log-phase culture supernatants. In the study referred to
[85], type C isolates growing in vitro maximally produced beta toxin during late-log phase.
Lethality induced by type C culture supernatants, or purified CPB, could be blocked by
preincubation with a monoclonal anti-CPB antibody, but not with a monoclonal anti-CPA
antibody (i.e. CPA is also produced by nearly all type C strains) [85].
To study lethality in a more adequate context of infection, we developed two mouse models
for type C infection 60]. In those models, mice were inoculated intragastrically or directly in
the duodenum with type C isolates, type C toxin mutants or purified CPB, along with trypsin
inhibitor. Type C strains or purified CPB reproduced neurological signs and mouse lethality.
Prior to the death of challenged mice, animals experienced sudden spastic muscle
contraction, tetany and opisthonous, supporting that the toxin(s) acts on the autonomic
nervous system. Two different type C null cpb mutants produced no lethality in mice,
clearly indicating that CPB is the main contributor to type C lethality [60].
A mutational analysis study [63] found that the arginine residue at position 212 of CPB is
important for mouse lethality. Tyrosine 191, its counterpart in S. aureus alpha-toxin, a
metabolite that has 28 % homology with CPB, is located in the putative binding domain
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[57]. Whether CPB must bind a specific organ, or cell type, is still unknown. Some evidence
has suggested that CPB may target the nervous system [59, 88, 89].
Another study determined that the CPB cysteine residue (at position 265) is not absolutely
required for lethal activity. However, this work showed that adding functional groups at
cysteine 265 (which induces steric hindrance) or changing residues 266, 268, and 275
caused a complete loss of lethal activity [90]. The authors proposed that the C-terminal
region of CPB is either required for beta toxin binding to receptor, if any, or for formation of
beta toxin oligomers.
The molecular basis of CPB-induced damage during type B or type C disease is under
investigation. Previous reports found that purified CPB forms pores in the membranes of
leukocyte-derived HL-60 cells or human umbilical vein endothelial cells [66, 68]. Studies
with recombinant toxin also demonstrated that CPB forms pores in bilayer lipid membranes.
Those channels induce K+ efflux and Ca2+, Na+ and Cl− influxes, which then produce cell
swelling and lysis. The mutation of arginine 212 in CPB to aspartate, previously shown to
increase the 50% lethal dose of CPB for mice by nearly 13-fold [63], significantly reduced
the ability of CPB to form channels. The size of the CPB pore has been calculated as
approximately 12 Å [59].
Purified CPB produces abundant dermonecrosis, edema and plasma extravasation when
directly injected into the skin of guinea pigs or mice [91, 92]. CPB also provokes the release
of TNF-α and IL-1β, as well as activates tachykinin NK1 receptors by a still unknown
mechanism [86, 91].
Gibert et al. (1997) [65] first reported that CPB induces cell rounding and detachment of
intestinal I407 cells [65]. In vivo, type B and type C isolates produce intestinal lesions
consisting of diffuse or multifocal hemorrhagic and necrotizing enteritis, mainly in the
ileum, with excess of sanguineous serous fluid in the abdominal cavity [79]. Similar
intestinal lesions have been observed after inoculating purified CPB into rabbit intestinal
loops [51, 87].
In recent work, Miclard et al. showed that CPB specifically binds vascular endothelial cells,
during peracute or acute cases of type C-induced disease in piglets or humans. The authors
reported that binding of CPB to those cells produced acute endothelial degeneration and
vascular necrosis [93, 94].
It is evident that CPB plays an important role in C. perfringens type C, and maybe in type B,
disease. Those diseases are often lethal with a fatal outcome within 48 h. The first target of
CPB during type C infection is the host intestine, where the toxin is highly active. This
damage to the intestinal epithelium might allow CPB and other toxins to be translocated into
the circulation to induce its lethal effects.
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EPSILON TOXIN (ETX)
Structure and Mechanism of Action
The main properties of epsilon toxin (ETX) are summarized in Table 3. ETX is an example
of an aerolysin-like, pore-forming toxin. C. perfringens ETX and C. septicum alpha-toxin
are structurally related to aerolysin although ETX shows no significant sequence homology
with aerolysin at the amino acid level. ETX and C. septicum alpha-toxin form heptameric
pores, like aerolysin, and are very potent cytolysins [3].
ETX is considered the major virulence factor of C. perfringens types B and D [19]. This
toxin causes blood pressure elevation, increased contractility of smooth muscle, vascular
permeability increase, as well as brain and lung edema in multiple animal species, while in
goats ETX also causes colitis [79, 95]. ETX is the third most potent clostridial toxin after
botulinum toxin and tetanus toxin, with a mouse lethal dose of 100 ng/kg [3]. ETX is
secreted as a prototoxin (32,981 Da) [96], which is converted into a fully active toxin
(~1000 times more toxic than the prototoxin) when activated by proteases such as trypsin,
chymotrypsin, and a metalloproteinase named lambda toxin that is produced by C.
perfringens [42, 97, 98].
ETX is also active on a few cell lines, including Madin Darby Canine Kidney (MDCK) and
to a lesser extent human leiomyoblastoma (G-402) [99, 100]. This toxin also kills guinea-pig
and rabbit peritoneal macrophages in vitro, but had no demonstrable effect on other cells
from guinea pigs, rabbits, mice, sheep or goats [101, 102]. When ovine, caprine and bovine
aortic endothelial cells were challenged with ETX in vitro, no morphological alterations
were observed in these cells even when large doses of toxin were used for several hours
[102]. In the study referred to [102] it was speculated that the absence of damage to aortic
endothelial cells was due to the need for ETX to act in concert with elements present in the
living animal but not in vitro and/or differences between endothelial cells of the brain and
those in the aorta [102].
In MDCK cells, marked swelling is observed in the first phase of intoxication, followed by
blebbing and membrane disruption [103]. ETX binds to the MDCK cell surface,
preferentially to the apical site, and recognizes a putative specific membrane receptor which
is not present in insensitive cells. Binding of the toxin to its receptor leads to formation of
large membrane complexes (about 155 kDa) which are very stable when the incubation is
performed at 37°C [103]. In contrast, the complexes formed at 4°C are dissociated by SDS
and heating [103]. The cytotoxicity in MDCK cells is associated with pore formation that
causes a rapid loss of intracellular K+, an increase of Cl− and Na+, with an increase of Ca++
occuring later. In polarized MDCK cells, ETX induces a rapid and dramatic increase in
permeability and it is thought that pore formation in the cell membrane is likely responsible
for the permeability change of cell monolayers. Actin cytoskeleton and organization of tight
and adherens junctions are not altered, and the paracellular permeability to macromolecules
is not significantly increased upon ETX treatment [104, 105]. Toxin-dependent cell
signaling leading to cell necrosis is not yet fully understood, but it includes ATP depletion,
AMP-activated protein kinase stimulation, mitochondrial membrane permeabilization, and
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mitochondrial-nuclear translocation of apoptosis-inducing factor, which is a potent caspase-
independent cell death factor [104].
In the brain, microvascular endothelial damage by this toxin appears to be the fundamental
cause of cerebral parenchymal injury and lesions occur in an apparently dose- and time-
dependant manner. Large doses of circulating toxin produce a severe, generalized vasogenic
cerebral edema and an acute or peracute clinical course to death. With lower doses in
partially immune animals, bilaterally symmetrical focal necrosis, occurs in certain
selectively vulnerable brain regions [106]. The precise pathogenesis of the brain damage is
unresolved, but the following sequence of events was proposed by Buxton and Morgan
(1976): ETX reacts with specific receptor sites in the brain endothelium, causing vascular
endothelial cells to degenerate. This alters fluid dynamics, which in turn causes the astrocyte
end-feet to swell and rupture. Serum proteins and eventually red blood cells leak out and the
resultant brain edema and haemorrhage produce parenchymal necrosis, which is responsible
for the clinical nervous signs and the histopathological changes seen during acute
intoxication of sheep and occasionally in goats.
In addition, degenerative and necrotic changes have been described in brain neurons of rats
subacutely intoxicated with ETX even before vascular changes in the brain were evident
[107]. Finnie et al. (1999) [107] suggested that after gaining access to the brain tissue by
producing an increase in vascular permeability, ETX later exerts a direct cytotoxic effect on
neurons. It was demonstrated that ETX passes through the blood-brain barrier and
accumulates specifically in the brain [106, 108–110]. ETX toxin binds with high affinity to
rat brain synaptosomes [111], and limited evidence suggests that the receptor might be a
sialoglycoprotein [109, 111, 112]. The neurological disorders observed in several animal
species seem to result from ETX action on hippocampus, leading to an excessive release of
glutamate [108, 113, 114].
In summary, ETX would act on the brain by affecting vascular permeability but also by
direct action on neurons. The precise target cell in host and mechanism of ETX action on
neuronal cells remain to be elucidated.
Genetics of etx
The ETX gene (etx) is localized on conjugative plasmids [51, 115], with most type B
isolates possessing the same ~65 kb etx plasmid that also carries the gene encoding beta2
toxin [115]. The etx gene in type B, and some type D, isolates is flanked by IS1151 and a
gene related to the transposase (tnpa) gene from Tn3 transposons that lie upstream of etx. A
region with similarity to transposases from S. aureus and Lactococcus is located
downstream from etx [115–117].
Role of ETX in Animal Diseases
ETX-producing C. perfringens type D strains are the most common cause of clostridial
enterotoxemia in sheep and goats (Table 2). Since the gross and histological changes
observed in type D enterotoxemia have been reproduced by intravenous inoculation of ETX
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in sheep and goats [118], there is little doubt that the pathogenesis C. perfringens type D
enterotoxemia is largely mediated by ETX.
C. perfringens type D produces an acute, subacute, or chronic neurological condition in
sheep, characterized by sudden death or neurological and respiratory signs, including
blindness, opisthotonos, convulsions, bleating, frothing from the mouth, and recumbency
with paddling immediately before death. Diarrhea is occasionally observed, although this is
not a common clinical sign in sheep [79, 119].
When present, intestinal gross changes consist of hyperemic small intestine mucosa with
slight to marked red fluid contents. Colitis may occur, but is not a consistent finding in
sheep enterotoxemia. Several gross findings, such as excess pericardial, pleural, and/or
abdominal fluids (with or without fibrin strands), which may clot on exposure to air, serosal
petechiation, and lung edema are frequently seen [79]. Gross changes in sheep are rarely
observed in brain, and consist of herniation of the cerebellar vermis (cerebellar coning) in
acute or subacute cases and focal symmetrical encephalomalcia (FSE), in chronic cases. FSE
is characterized by dark hemorrhagic foci in corpus striatum, thalamus, midbrain, and
cerebellar peduncles and white matter [120–122]. The kidney lesion from which one of the
common names of the disease is derived (pulpy kidney disease) is likely to be a postmortem
change [80, 123].
Microscopic changes in the brain of sheep with type D infection are unique and
pathognomonic, and they are present in approximately 90% of cases [120, 124]. They
consist of perivascular proteinaceous edema (microangiopathy) in the brain [120] (Fig. 2). In
the rarely observed chronic form of the disease, necrosis of white matter, grossly known as
FSE, can be observed [122]. This lesion is usually multifocal and characterized by
degeneration of white matter, hemorrhage, and astrocyte and axonal swelling. Perivascular
edema and degeneration, and necrosis of brain parenchyma, are always bilateral and
symmetrical, and they have been described most frequently in corpus striatum, thalamus,
midbrain, cerebellar peduncles, and cerebellar white matter [120, 121]. These areas are not
exclusively affected, and lesions can sometimes be seen in other parts of brain, such as
cortex and hippocampus [120]. Usually, no significant histological changes are found in the
intestine of sheep dying from enterotoxemia [124, 125]. Histological changes were not
observed in kidneys of experimentally inoculated lambs necropsied immediately after death
[124], supporting suggestions that these lesions are due to postmortem change.
In goats, type D produces acute, subacute, or chronic disease as well. The acute form occurs
more frequently in young, unvaccinated animals and is clinically similar to the acute disease
in sheep [126, 127]. The subacute form is more frequently seen in adult goats [128],
vaccinated or not, and is characterized by hemorrhagic diarrhea, abdominal discomfort,
severe shock, opisthotonos, and convulsions. The disease may result in death 2–4 days after
onset [41, 127], but some animals recover. Adult animals, often vaccinated, can also exhibit
chronic disease [128], which is characterized by profuse, watery diarrhea (often containing
blood and mucus), abdominal discomfort, weakness, anorexia, and agalactia [126]. This
chronic form may last for days or weeks [129].
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Gross changes in acute caprine type D enterotoxemia are similar to those in the ovine
disease. In the chronic form of the disease in goats, fibrinohemorrhagic colitis with
occasional involvement of the distal small intestine seems to be the most consistent lesion
[126]. A combination of the findings in acute and chronic forms of disease are frequently
seen in subacute forms. The so-called pulpy kidney has not been reported in caprine
enterotoxemia, nor has cerebellar herniation or FSE.
In goats, there are few descriptions of histological changes in type D enterotoxemia, and
changes in brain are not considered a consistent feature of caprine enterotoxemia.
Nevertheless, perivascular edema and degeneration of white matter, similar to those
observed in sheep, can be observed in cases of acute and subacute caprine enterotoxemia
[130].
In addition, subacute and chronic type D enterotoxemia in goats are characterized by
fibrinonecrotic (pseudomembranous) colitis with large numbers of intralesional Gram-
positive bacilli [128]. Microscopic lesions in kidney are not characteristic of goat
enterotoxemia.
In cattle there are few reports about natural cases of type D enterotoxemia, and information
about clinical and pathologic findings of the disease in this species is scant and frequently
contradictory [131–133]. A condition called enterotoxemia of cattle, allegedly produced by
C. perfringens type D, is described in textbooks [55,134] but confirmation of the etiology of
this condition remains unestablished. The occurrence of FSE, similar to the lesion observed
in type D enterotoxemia of sheep, has been described by several authors in cattle [134–139]
but to date no causal relationship between these lesions and C. perfringens type D has been
established. Recently, natural type D enterotoxemia was described in two young calves, in
which the disease was confirmed by the presence of perivascular proteinaceous edema in the
brain and detection of ETX in intestinal contents [140]. These seem to be the first confirmed
cases of type D enterotoxemia in cattle.
The effects of intravenous ETX have been studied in sheep [118, 120], goats [118], cattle
[46, 141], mice [85, 142, 143] and rats [107]. The toxin produces increased vascular
permeability in many tissues, the most significant effects of which are acute pulmonary and
cerebral edema with albumin extravasation. This has been demonstrated by
immunohistochemistry, which shows strong perivascular immunoreactivity around blood
vessels showing perivascular edema. Also, in rats given ETX intravenously, widespread
upregulation of aquaporine 4 (a member of the membrane water-channel proteins, which is
important in the regulation of water balance in the brain and facilitates reabsorption of
excess fluid) was observed in astrocytes [144]. These results suggest that aquaporin 4 has a
role in the clearance of edema fluid from brains damaged by ETX. The administration of
formalinized epsilon prototoxin to mice prevented leakage of horse radish peroxidase from
the brain vasculature of mice given ETX via the same route [145, 146]. Based on these
results, it was suggested that ETX exerts its effects through specific receptor sites on the
vascular endothelium and that antigenically similar formalinized epsilon prototoxin blocks
this effect [145].
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In mice given intravenous ETX the granular layer of the cerebellum seems to be the area
most frequently affected and lesions progress from an initial vasogenic edema to malacic
foci with bilateral symmetry, and with a predilection for the white matter [142].
Ultrastructurally the initial findings include swelling of astrocytes, especially their
perivascular extensions and astrocytes in the cerebellum appeared to be particularly sensitive
to ETX. These changes are quickly followed by severe endothelial damage with the
endothelial cytoplasm becoming attenuated, vacuolated and very electron-dense [143].
Studies with immunohistochemistry demonstrated that after ETX administration to rats,
there is rapid opening of the blood-brain barrier to albumin [147]. Renal tubular lesions were
described in mice inoculated experimentally with ETX, but not in ruminants.
Niilo et al. [46] induced disease by intraduodenal inoculation of whole cultures of C.
perfringens type D and dextrin in eight calves. Two of the animals presented acute
neurological signs and severe pulmonary edema, hydrothorax, hydroperitoneum and serosal
hemorrhages, while the other six did not show clinical or pathological changes. However, no
histologic lesions were described in any of the animals [146]. Uzal et al. [141] reported
acute loss of consciousness, hyperaesthesia, intermittent tonic and clonic convulsions,
recumbency and dyspnea in calves inoculated intravenously with C. perfringens type D
ETX. These calves showed severe acute pulmonary edema and varying degrees of
perivascular proteinaceous edema in the internal capsule, thalamus and cerebellum. While
the gross and histologic findings described in the calves inoculated with ETX were very
similar to changes in acute enterotoxemia of sheep, the experimental procedures involved
intravenous injection of ETX and this cannot, therefore, be considered a model of natural
disease. Recently, a disease clinically and pathologically identical to ovine enterotoxemia
was reproduced in cattle by intraduodenal inoculation of whole cultures of C. perfringens
type D [148], which seems to fulfill Koch’s postulates for type D disease in cattle.
IOTA TOXIN
Structure and Mechanism of Action
The main properties of iota toxin (ITX) are summarized in Table 3. C. perfringens ITX is a
clostridial binary toxin. These toxins have a common structure consisting of two
independent protein components that are not covalently linked, one being the binding
component (Ib, 100 kDa), and the other the enzymatic component (Ia, 45 kDa) [149]. Both
components are required for biological activity. The crystal structure of Ia has been solved,
which revealed some resemblance to the ADP-ribosylating B. cereus vegetative insecticidal
protein [150].
The ITX family components are synthesized during exponential growth phase and secreted
by means a signal peptide as inactive proteins. They are proteolytically activated by trypsin
or chymotrypsin, removing a 20 kDa N-terminal peptide from the binding component (80
kDa for the active form) and 9 to 11 N-terminal residues from the enzymatic component
[151]. Ib triggers the internalization of Ia into the cell by receptor-mediated endocytosis
[152, 153]. The mature binding component recognizes a specific cell membrane receptor
[154] and then heptamerizes to form ion permeable channels, allowing the enzymatic
component to escape from endocytic vesicles into the cytosol upon an acidic pulse [65, 133,
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149, 155, 156]. Once activated by trypsin, Ib forms heptamers that insert into the membrane
and form pores permitting the passage of molecules such as ions. Ib remains on the cell
surface up to 3 h and mediates the endocytosis of Ia molecules [157].
The most prominent effects of ITX include depolymerization of actin filaments and increase
of G-actin monomers. This effect results from Ia-mediated ADP-ribosylation of G-actin at
Arg-177 [150]. The intermediate filaments are also disorganized, whereas the microtubules
are not affected. The final result of this is change in morphology (rounding), inhibition of
migration and activation of leucocytes [158], inhibition of smooth muscle contraction,
impairment of endocytosis, exocytosis, and cytokinesis. Depolymerization of the actin
cytoskeleton by ITX induces disorganization of tight and basolateral intercellular junctions
with a subsequent increase in permeability of cultured intestinal cell monolayers [157].
Genetics of itx
The components of ITX are encoded by two genes, iap (~1160 nt) and iab (~2,630 nt).
These genes form an operon that also includes an intermediate region composed of 243 non-
coding nucleotides. Transcription of both ITX genes is driven by a promoter located
upstream of the iap gene [152]. Molecules that regulate the transcription of the ITX genes
have not yet been discovered.
The iap and iab genes have been found on large, potentially conjugative, plasmids of ~97 kb
or ~135 kb. Those plasmids typically carry a silent enterotoxin (cpe) gene, the IS1151
element and a tcp locus (18). Interestingly, a study by Li et al. [18] suggested that a mobile
genetic element, carrying iap and ibp genes, could have inserted onto a tcp-carrying
enterotoxin plasmid in a type A isolate to create a progenitor ITX-plasmid. This plasmid
then may spread via conjugation to other type A isolates, converting them to type E [18].
Role of ITX in Animal Diseases
Toxinotype E enteric infection of domestic animals was first reported in the late 1940s, and
these infections have generally been considered a rare occurrence. As with type A infections
and CPA, infections by C. perfringens type E are usually assumed to be mediated by ITX
(Table 2), although no definitive evidence in this regard has been provided. C. perfringens
type E produces enterotoxemia in rabbits. A very similar disease, thought to be mediated by
a iota-like toxin, is produced in rabbits by Clostridium spiroforme. However, because of
cross reactivity between C. perfringes type E and C. spiroforme toxins with the diagnostic
methods currently available, it is thought that some previously reprted outbreaks of
entropathies associated with C. perfringensmay have been due to C. spiroforme.
Both diseases are clinically characterized by diarrhea and loss of condition and characteristic
necropsy changes include hemorrhages of the cecal serosa and mucosa, sometimes with
involvement of the distal ileum and proximal colon, and the presence of watery mucoid
content in these organs. Histologically, there is an acute necrosis of the superficial
epithelium with relative sparing of the crypt epithelium, and submucosal hemorrhage and
transmural hemorrhage [159].
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Toxinotype E is an occasional cause of hemorrhagic enteritis and sudden death in beef
calves [32, 160]. Type E disease has rarely been described in sheep and goats [43]. The role
of ITX in these infections has not been elucidated.
Clostridium Perfringens Beta 2 Toxin (CPB2)
In recent years, a new C. perfringens toxin known as beta2 toxin (CPB2) has been widely
reported as a potential contributor to C. perfringens related enteric diseases. The cpb2 gene
can be carried by all C. perfringens types [18, 85, 161]
Structure and Mechanism of Action
The main properties of CPB2 are summarized in Table 3. Gibert et al. [65] first cloned the
CPB2 toxin gene (cpb2) from C. perfringens CWC245, which was isolated from a piglet
suffering from necrotizing enterocolitis [65]. The cloned sequence revealed an open reading
frame of 265 amino acids, including a 30 amino acid signal sequence absent from the 28
kDa mature toxin [65, 162]. The novel CPB2 has no significant homology with beta toxin or
other known bacterial toxins [65, 163, 164]. To date very few studies have been conducted
to determine the biological activity of CPB2. An early report suggested that the toxin
behaves similarly to CPB [165] and Gibert et al. (1997) [65] demonstrated the cytotoxic
effects of CPB2 on Chinese hamster ovary and human intestinal embryonic 1407 cedll lines.
This cytopathology included cell rounding, membrane blebbing and detachment from the
culture matrix [65]. The toxin did modify small G proteins such as actin, either by ADP-
ribosylation or by UDP- glucosylation [65]. Other cell lines, such as CaCo2 cells have also
been shown to be sensitive to the cytotoxic effects of CPB2 [161]. The cytopathic effects
demonstrated by Fisher et al. [85] were similar to those described previously and the toxin
induced cell death 50 (TCD50) was 0.3 – 4 μg/ml for the purified native CPB2, and a
recently described variant CPB2 [65]. Based on these studies, it was suggested that CPB2
toxin could act as a potential pore-forming toxin similar to other enterically-active clostridial
toxins. The toxin was shown to be highly susceptible to proteolytic cleavage by trypsin [65].
The minimal lethal dose (LD50) of CPB2 for mice, as described previously [65], was 0.3 μg
by the i.v. injection route. A mouse i.v. injection model demonstrated a weak correlation
between CPB2 levels in late log-phase culture supernatants of C. perfringens type C isolates
and the LD50 [85], suggesting that CPB2 could be a minor contributor to the lethality of C.
perfringens type C isolates. Gibert et al. [65] showed that CPB2 toxin caused intestinal
hemorrhage and necrosis in the guinea pig ligated loop model.
Detailed structure-function studies for CPB2 have not been demonstrated. However, a
recombinant Clostridium perfringens CPB2 derivative has been purified using Glutathione
sepharose affinity chromatography. That toxin was then crystallized using the batch-under-
oil technique. Crystallographic analysis of this CPB2 crystal showed that the triangular
prism shaped crystals measuring 200 microns belonged to primitive rhombohedral space
group R3, diffracting up to 2.9 Å [166].
Uzal et al. Page 16
Open Toxinology J. Author manuscript; available in PMC 2014 February 07.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Genetics of CPB2
The cpb2 toxin gene is transcribed during vegetative growth, especially during the
exponential phase and regulation by the VirS/VirR two-component regulatory system [73].
The cpb2 gene is present on C. perfringens type D isolates on plasmids 48 kb to 110 kb in
size [19]. In these isolates, the gene is either present on the same plasmid carrying the etx
gene or on a different plasmid. In type E isolates, cpb2 gene is present on plasmids sizes
varying from 70 kb to 90 kb. The gene is always present on different plasmid carrying the
iota toxin gene (itx) [18]. In recent studies (authors’ unpublished observations), the cpb2
gene was found to be present on a 65 kb plasmid that also carries the etx gene, in C.
perfringens type B isolates.
Role of CPB2 in Animal Disease
Over the past decade CPB2 has been associated with enteric diseases in a wide range of
animals (Tables 3 and 4) including swine [65, 162, 167–170], cattle [28, 32, 171–174],
horses [33, 35–39], sheep and goats [175, 176], and wild animals such as deer [177] and
bears [178, 179]. The clinical signs observed in CPB2-mediated enteric diseases range from
pasty to watery diarrhea with blood in feces, abdominal pain, and loss of body condition. It
is hypothesized [165] that CPB2 toxin may act in synergy with other major toxins of C.
perfringens in the production of necrotic and hemorrhagic enteritis. Circumstances
provoking enteric dybiosis, and other predisposing factors, could lead to diseases in these
animals [165].
Based on the reported findings related to the pathology of C. perfringens encoding CPB2-
related enteritis seen in food producing and wild animals [28, 32, 33, 35, 81, 169, 171, 175,
177, 178], the gross pathology is characterized by hemorrhage and necrosis of the small and
large intestines. Other prominent gross pathologic lesions include swollen, hemorrhagic
mesenteric lymph nodes, as well as thickened and congested abomasal walls. The
characteristic histological lesions include degenerated and necrotic desquamated epithelial
cells, cell debris, inflammatory cells, fibrin and variable numbers of bacterial vegetative
cells and spores. The pathologic lesions observed suggest that CPB2 toxin is a primary
enteric toxin affecting the nutrient absorptive capacity of the intestine, thereby debilitating
the affected animal.
Despite several recent publications suggesting that CPB2 might be implicated in intestinal
diseases of several animal species, most of the evidence to support this is based on isolation
of cpb2- positive C. perfringens strains from affected animals. However, because cpb2
positive strains can also be found in the intestine of many normal animals, the significance
of this finding is not clear. A much larger proportion of strains carrying the cpb2 gene was
found in the intestine of pigs with diarrhea than in normal control animals, which strongly
suggests that CPB2 is implicated in pig enteritis. However, the same does not seem to be
true for other animal species and the role of CPB2 in enteric disease of those animals
remains, therefore, undetermined.
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CLOSTRIDIUM PERFRINGENS ENTEROTOXIN (CPE)
Structure and Mechanism of Action
The main properties of CPE are summarized in Table 3. CPE is a 319 amino acid protein
consisting of an N-terminal domain, which is important for pore formation and cytotoxicity,
and a C-terminal domain that mediates receptor binding [180]. Although CPE lacks
sequence homology with other toxins, its C-terminal receptor-binding domain structurally
resembles that of some Bacillus thuringiensis cry toxins [181].
CPE action starts when the toxin binds to claudin receptors (claudins are important
components of the tight junctions made by epithelial and endothelial cells), forming a small
complex [182]. Several small complexes then oligomerize on the membrane surface to form
a prepore named CH-1 [183]; CH-1 minimally contains six copies of CPE, claudin receptor,
and some non-receptor claudins that are likely interacting with the claudin receptors [183].
After its formation, the CH-1 prepore inserts into the membrane bilayer to generate a cation-
selective pore [182]. The resultant calcium influx activates apoptotic and oncotic cell death
pathways that cause morphologic damage to the CPE-treated cells. This morphologic
damage exposes the basolateral surface of the cell, allowing CPE to interact with occludin
and additional claudins to form a second CPE-complex named CH-2 [183]. Formation of
CH-2 triggers internalization of occludin (and probably claudins), which may contribute to
paracellular permeability changes and diarrhea.
All tested mammalian species are sensitive to CPE [184]. This toxin affects all small
intestinal regions but is most active in the ileum [184, 185]. CPE has only weak effects on
the colon of rabbits [184] or human colonic tissue ex vivo [48]. In the ileum, CPE causes
villus shortening and epithelial desquamation [50, 184], and such damage appears necessary
for accumulation of fluids and electrolytes in the lumen [186].
Genetics of cpe
The gene (cpe) encoding CPE can reside on either the chromosome or on plasmids [187,
188]. Most human food-poisoning isolates carry cpe on the chromosome [180], and recent
multi locus sequence typing (MLST) studies suggest these chromosomal cpe isolates are
relatively divergent from other C. perfringens isolates [189]. In contrast, cpe-positive
isolates recovered from diseased animals or humans suffering from nonfoodborne human
gastrointestinal disease typically carry their cpe gene on large plasmids [187, 190].
In type A isolates, there are two major cpe plasmid families [189]: i) a family of ~75 kb
plasmids that also carry the beta2 toxin gene (cpb2); ii) a family of ~70 kb plasmids lacking
the cpb2 gene. These two cpe plasmid families in type A isolates share a conserved 35 kb
region. Some, if not all, cpe plasmids of type A isolates can transfer between C. perfringens
via conjugation [191], probably because they possess the same tcp locus that mediates
transfer of C. perfringens tetracycline resistance plasmid pCW3 [192]. Some type C and D
isolates also carry a plasmid-borne cpe gene [19, 85], although those plasmids do not appear
to be closely related to the cpe plasmids of type A isolates (unpublished). Interestingly, most
type E isolates carry silent cpe sequences on their iota toxin-encoding plasmids, which are
often related to cpe plasmids of type A isolates [18].
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During human food poisoning, CPE-positive strains are ingested and then sporulate in the
intestines [180, 193]. CPE is expressed during sporulation [180], in a process involving
regulation by the SpoOA master regulator of sporulation [194] and alternative sigma factors
[195]. The toxin then accumulates intracellularly until lysis of the sporangium, releasing
CPE into the intestinal lumen.
The Role of CPE in Animal Diseases
Experiments using isogenic mutants have clearly shown that CPE production is important
for C. perfringens type A food poisoning or nonfoodborne gastrointestinal (GI) disease
isolates to cause diarrheal symptoms in experimental animals [50]. Coupled with extensive
epidemiologic evidence, these findings support CPE as an important virulence factor for C.
perfringens type A food poisoning or CPE-associated nonfoodborne human GI disease
[180].
In contrast to the well-established role of this toxin in human GI disease, the data
implicating CPE in animal disease remains more ambiguous (Table 2). Animals with
diarrhea are rarely tested for the presence of CPE in their feces and diagnostic criteria for
establishing CPE-mediated animals disease are lacking [81]. Nevertheless, there are case
reports [4, 34, 82, 196–200] suggesting CPE may cause GI disease in both domestic animals
(including dogs, pigs, horses, and goats) and possibly wild animals (such as penguins,
leopards and tortoises). For example, a relatively recent study definitively showed the
presence of CPE-positive, type A isolates and CPE in the small intestines of a goat kid
suffering from necrotic enteritis [189]. Additionally, fecal CPE and CPE-positive fecal
isolates have been associated with canine diarrhea [197] and it has been suggested that CPE-
positive strains can cause recurrent diarrhea in dogs [199].
Finally, in horses, fecal CPE was detected in ~20% of adults with diarrhea and ~30% of
foals with diarrhea [201]; thus supporting a role for this fecal toxin contributing to disease in
those animals, while no fecal CPE was detected in healthy adult horses or foals.
PERFRINGOLYSIN O OR THETA TOXIN (PFO)
Structure and Mechanism of Action
The main properties of PFO (also called theta toxin) are summarized in Table 3. PFO is a 54
kDa cytolytic toxin that binds to cholesterol-containing eukaryotic membranes. This toxin
forms a large oligomeric prepore complex on the membrane surface prior to insertion into
the cell membrane [202]. Structurally, PFO is comprised of 4 domains. The C-terminal
domain (domain 4) binds cholesterol and then a conformational change in domain three
exposes a β–hairpin that spontaneously inserts into the lipid bilayer [78, 202].
It has been proposed that the high affinity of PFO for cholesterol concentrates the toxin on
the target membrane, promoting oligomerization and membrane insertion [203]. As
mentioned, the proposed model of PFO pore formation includes the binding of water-soluble
PFO monomers to cholesterol of a lipid bilayer mediated by domain 4. However, domain 4
does not insert deeply into the membrane and is not directly involved in creating the pore.
Instead, PFO monomers bound to cholesterol and orientated perpendicularly to the
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membrane assemble and oligomerize to form a prepore complex [78]. The oligomers consist
of 40 to 50 monomers, forming on the membrane surface large arcs and rings that, after
insertion of their domain three loops, lead to large pores between 300 Å and 450 Å in
diameter [204].
Genetics of PFO
PFO is produced by all C. perfringens strains and the pfoA gene is located on the
chromosomal DNA near the origin of replication [163, 164, 205]. PFO is synthesized with a
27 amino acid signal peptide, and the mature protein consists of 472 amino acids (53 kDa)
[206].
The pfoA gene is directly regulated by the VirS/VirR two-component regulatory system
[22–24]. Once activated by the VirS sensor kinase, the VirR response regulator binds to
specific VirR boxes (VirR box 1 and VirR box 2) located upstream of the pfoA promoter, to
activate its transcription [207].
The signal(s) that activates the VirS/VirR two-component regulatory system is unknown.
The presence of enterocytes rapidly upregulates PFO production and transcription of the
pfoA gene, via the same VirS/VirR two-component regulatory system [26, 71]. More
recently, the C. perfringens Agr quorum sensing system was shown to regulate PFO toxin
levels and transcription of the pfoA gene in vitro [25, 26, 71]. Whether the Agr-secreted
factor activates, in vitro or in the presence of eukaryotic cells, the VirS sensor kinase
remains unknown.
Role of PFO in Animal Diseases
Gangrene—PFO participates with CPA in the production of local lesions of gangrene/
malignant edema in humans and animals [208]. When CPA and PFO knock-out mutants of
C. perfringens type A were used in a mouse model, elimination of both CPA and PFO toxin
genes removed most of the histopathological features typical of clostridial myonecrosis.
These effects were completely restored when the double mutant was complemented with the
alpha-toxin structural gene. However, restoring only PFO activity produced variable results.
Reconstitution of both toxins produced histopathology similar to that observed with the
alpha-reconstituted strain (1). Studies using single PFO knock-out mutants of C. perfringens
have shown that PFO induces tissue destruction and an anti-inflammatory response.
However, the effects were less pronounced than those elicited by CPA and both toxins seem
to have a synergistic action in gangrenous lesions [209].
Since PFO knock-out mutants still cause murine myonecrosis, although less severe than wild
type type A strains, PFO is not considered essential for disease. Instead, PFO has the ability
to affect the host inflammatory response, particularly the PMNL influx into the myonecrotic
lesions. PFO has been implicated in the vascular accumulation of leukocytes within blood
vessels and the extracellular matrix of host tissues [11, 210, 211].
PFO and CPA stimulate leucocyte adherence, probably by increasing vascular leucostasis
and local ischemia. PFO is leukocytotoxic at high doses, and at a sublethal concentration it
significantly stimulates the production of ICAM-1 and adherent glycoprotein CD11b/CD18
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in endothelial cells, which contributes to leukostasis in vessels adjacent to gangrenous
lesions [11, 210]. The toxin effects on endothelial cells participate in disruption of
endothelial integrity resulting in local edema and ultimately in systemic shock and
multiorgan failure. Thus, PFO and CPA exhibit synergistic effects [52, 212].
Intestinal Infections—PFO might also have a synergistic effect with ETX. The effects of
purified CPA and PFO on the lethal activity of purified ETX were studied in a mouse model.
Mice were injected intravenously or intragastrically with CPA or PFO with or without ETX.
Sublethal doses of CPA or PFO did not affect the lethality of ETX when either was injected
together with the latter intravenously [213]. However, sublethal or lethal doses of CPA or
PFO reduced survival times of mice injected simultaneously with ETX versus animals given
ETX alone. When PFO was inoculated intragastrically with ETX, there was a reduction in
survival time. CPA did not alter the survival time when inoculated intragastrically with
ETX. These results suggest that both CPA and PFO have the potential to enhance the ETX
lethal effects during enterotoxemia in natural hosts such as sheep and goats [213].
CONCLUSIONS
For many years it has been thought that most deleterious effects of C. perfringens infections
in animals, and humans, are mediated by one or more of its powerful toxins. Toxins purified
from C. perfringens culture supernatants have greatly improved our understanding of how
these toxins mediate cellular damage. However, the specific role of individual toxins in C.
perfringens-mediated diseases has just recently started to come to light. The recent
improvement of animal models for C. perfringens infection and methods that inactivate
toxin genes (generating toxin knock outs) have now demonstrated the specific pathologic
role of several toxins of C. perfringens in animal and human disease. By observing a
reduced or lack of virulence in knock-out strains and then full virulence with the
complemented strains, the so called molecular Koch postulates have been fulfilled for
several C. perfringens toxins, including CPB, CPA, CPE and others. These now available
research tools are becoming very important in the field and are helping us: (1) to establish
the role of each C. perfringens toxigenic type in animal or human disease; (2) to investigate
the in vivo mechanism of action of their toxins; and (3) to develop more effective vaccines
that will prevent lethal diseases produced by these microorganisms.
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Fig. 1.
CPB-mediated gross pathology and histological damage of rabbit ileal intestinal loops.
Rabbit ligated intestinal loops were inoculated with a type C CN3685 isolate (WT), isogenic
single toxin mutants, purified CPB or medium (unioculated TGY medium) and then
incubated for 6 h. A) Gross pathology. Loops inoculated with the WT, ΔpfoA, Δcpa, or
purified CPB are severely hemorrhagic and distended with fluid. No significant gross
abnormalities are observed in the loops inoculated with two different Δcpb mutants or sterile
TGY medium. B) Histology. Control loops inoculated with sterile TGY, and loops
inoculated with the Δcpb mutant showed normal intestinal villi with a well-preserved
epithelium and lamina propria. Loops inoculated with wild type CN3685 (WT) or the
complemented Δcpb/cpb showed histological damage consisting of necrosis and loss of
epithelium, necrosis of lamina propria, blunting of the villi, hemorrhage of the mucosa and
diffuse neutrophilic infiltration of mucosa and sub mucosa (Reproduced from Sayeed et al.
2008, with permission from Wiley Blackwell publisher).
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Fig. 2.
A) Proteinaceous perivascular edema in the brain of a lamb with type D enterotoxemia. The
edema of the brain in this disease is mediated by the action of ETX. HE, 250x. (Reproduced
from Uzal F.A., Ortega Porcel J. and Corpa Arenas J.M., 2008. Enterotoxemia ovina y
caprina. Cuadernos de Campo, Merial Ed., Barcelona, Spain). B) Brain from a normal lamb
is shown for comparison. HE, 250x.
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Table 4
Epidemiological Studies Linking CPB2 and Diseases in Different Animals
Toxinotype Species Disease Reference
A Swine Necrotic enteritis Gibert et al. (1997)
A Swine Diarrhea Klaasen et al. (1999)
A Swine Diarrhea, gastroenteritis Waters et al. (2003)
A Swine Diarrhea Bueschel et al. (2003)
A Swine Enteritis Jost et al. (2005)
A Swine Enteritis Jost et al. (2006)
A Swine Neonatal diarrhea Hendriksen et al. (2006)
A Bovine Enterotoxaemia Manteca et al. (2002)
A Bovine Hemorrhagic bowel syndrome Dennison et al. (2005)
A Bovine Enterotoxaemia Lebrun et al. (2006)
A Bovine Hemorrhagic bowel syndrome Ceci et al. (2006)
A Bovine Hemorrhagic enteritis Songer & Miskimins (2005)
A, E Bovine Neonatal diarrhea Ferrarezi et al. (2008)
A Equine Fatal and Non fatal Typhlocolitis Herholz et al. (1999)
A Equine Typhlocolitis Bacciarini et al. (2003)
A Equine Type A myonecrosis Choi et al. (2003)
A Equine Gastrointestinal diseases Waters et al. (2005)
A Equine Typhlocolitis Vilei et al. (2005)
A Equine Enterocolitis Timoney et al. (2005)
A Caprine Enterotoxaemia Dray et al. (2004)
D Caprine Enterotoxaemia Uzal et al. (2008)
A Cervidae Clostridial enterotoxaemia Embury-Hyatt et al. (2005)
? Ursidae Necrotic and Hemorrhagic enteritis Greco et al. (2005)
A Ursidae Normal flora Jores et al. (2008)
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